Riyadh: King Faisal Specialist Hospital and Research Centre (KFSHRC) has signed five key international agreements during the Saudi-US Investment Forum 2025, underscoring its commitment to advancing medical innovation and strengthening strategic global collaborations. The agreements were formalized during a high-level roundtable session titled “Next-Generation Healthcare: Saudi-US Collaboration in Biotechnology and Digital Health”, held at the King Abdulaziz International Conference Center in Riyadh.
According to Saudi Press Agency, CEO of KFSHRC Dr. Majid bin Ibrahim AlFayyadh expressed his gratitude for the unwavering support from Custodian of the Two Holy Mosques King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. He emphasized that this support has empowered KFSHRC to become a leading global healthcare institution.
Dr. AlFayyadh outlined the hospital’s transformative journey toward clinical excellence, enhanced research and education, and financial sustainability in alignment with the goals of Saudi Vision 2030. He stressed the importance of investing in advanced medical technologies to improve spending efficiency and ensure high-quality treatment outcomes. KFSHRC’s adoption of cutting-edge treatments such as CAR-T cell therapy and robotic surgeries, along with its expertise in organ transplantation and personalized medicine, reduces the need for patients to seek treatment abroad and reinforces the Kingdom’s position as a regional hub for specialized healthcare.
The agreements include a memorandum of understanding with Cleveland Clinic focused on autism and neuroscience, a tripartite agreement with Qiddiya Investment Company and Cleveland Clinic in sports medicine and performance, a collaboration with Germfree for advanced laboratory development, an agreement with Medtronic to supply cardiac center equipment and establish a new catheterization unit, and a memorandum of understanding with ImmunityBio-alongside the King Abdullah International Medical Research Center and the Ministry of Investment-to develop a national biotechnology platform in immunotherapy for cancer and infectious diseases.
The release added that these strategic agreements reflect KFSHRC’s ongoing dedication to fostering innovation and international cooperation, while supporting the Kingdom’s efforts in technology localization and healthcare advancement.
KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centres for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world’s best 250 hospitals and included in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit www.kfshrc.edu.sa or contact our media team at [email protected]
